web analytics
$1,000,000,000$186,000,000/EBITDA
Chemical manufacturing for sale

The proposed project entails the development of a state-of-the-art, vertically integrated chlor-alkali and downstream specialty chemical manufacturing cluster in Kazakhstan. Capitalizing on abundant domestic salt reserves, compe ...

$1,000,000,000$186,000,000/EBITDA
$186,000,000
$44,000,000$3,700,000/EBITDA

A leading independent multi-omics service providers in the Americas. The Company provides a comprehensive portfolio of next-generation sequencing (NGS), proteomics, metabolomics, epigenomics, and bioinformatics solutions to resear ...

$44,000,000$3,700,000/EBITDA
$3,700,000
€4,500,000€1,250,000/EBITDA
industrial chemicals company Europe

The Company is a well-established Italian manufacturer and distributor of specialty chemical products, with a long-standing heritage rooted in post-war industrial development. Over decades, the business has evolved into a recogniz ...

€4,500,000€1,250,000/EBITDA
€1,250,000
$25,000,000TBD/EBITDA

US company owns producer and processors Tier 3 licenses in Washington state. 49,000 sq ft building (where the Flower room is 11,500 sq. ft. and Mather and Veg is 7,700 sq. ft.) is currently finished on this (10 acres) site. ...

$25,000,000TBD/EBITDA
TBD
€15,000,000€800,000/EBITDA
Produttore Leader Cannabis franchising 100+ negozi in Europa

The business was born in 2017 from the idea of nine members who came from different fields but shared the same passion for hemp and its boundless worlds. After opening the first official shop in the same year, several openings fol ...

€15,000,000€800,000/EBITDA
€800,000
$40,000,000$3,000,000/EBITDA

The company was founded in the district Punjab India, 1982 with a purpose of manufacturing Active Pharmaceutical Ingredients. The company is an active pharmaceutical ingredient (API) manufacturing company that manufactures the ...

$40,000,000$3,000,000/EBITDA
$3,000,000
$12,000,000TBA/EBITDA
制药

This company for sale is a healthcare company based in Bangalore, India. The business is involved in the manufacturing and supply of medicines and nutritional supplements to people across the globe (Quality standards as specified ...

$12,000,000TBA/EBITDA
TBA
property

Central Asian Chlor-Alkali & Chemicals Manufacturing Platform

EBITDA

$186,000,000

Gross

$620,000,000

Price

$1,000,000,000
property

American Leading Life Sciences Research Services Platform

EBITDA

$3,700,000

Gross

$57,000,000

Price

$44,000,000
property

Established Italian Producer of Industrial & Consumer Chemical Solutions

EBITDA

€1,250,000

Gross

€5,100,000

Price

€4,500,000
property

Industrial Cannabis Grow and processing facility Center

EBITDA

TBD

Gross

TBD

Price

$25,000,000
property

Leading Cannabis Producer with Over 100 Franchise Shops Across Europe

EBITDA

€800,000

Gross

€3,750,000

Price

€15,000,000
property

40 Year Old Pharmaceutical Manufacturing Business

EBITDA

$3,000,000

Gross

$25,000,000

Price

$40,000,000
property

40 Year Old Rx-pharma Manufacturing Business

EBITDA

TBA

Gross

$1,900,000

Price

$12,000,000

Manufacturing - Chemicals Pharma & Life Sciences For Sale

The proposed project entails the development of a state-of-the-art, vertically integrated chlor-alkali and downstream specialty chemical manufacturing cluster in Kazakhstan. Capitalizing on abundant domestic salt reserves, competitive operating fundamentals, and strategic Eurasian logistics corridors, the project is structured to substitute high-volume chemical imports and capture expanding export demand across Central Asia.

Key Investment Metrics

Metric Target Value
Total Capital Expenditure (CapEx) US$1.06 Billion
Project Net Present Value (NPV) US$62.2 Million
Internal Rate of Return (IRR) 15.2%
Simple Payback Period 5.7 Years
Discounted Payback Period 9.1 Years
Primary Target Markets Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan

Strategic Value Drivers

  • Upstream Feedstock Security: Kazakhstan produces 1.2–1.9 million tonnes of salt annually (1.85 million tonnes in 2024), anchored by the Kyzylorda region (>70% of national output). This captive, low-cost supply provides a sustainable baseline margin advantage across the chlor-alkali chain.
  • Significant Import-Substitution Market: Central Asia currently imports over US$700 million annually of PVC, caustic soda, and surfactants—a market projected to approach US$1.0 billion by 2030. The cluster directly targets these import flows while servicing structural deficits in local manufacturing and infrastructure.
  • Comprehensive Value-Chain Integration: The project extends basic chlor-alkali capacity into premium, margin-resilient downstream segments:
    • Upstream & Intermediates: Caustic Soda (NaOH), Chlorine (Cl₂), Hydrogen (H₂), Hydrochloric Acid (HCl), Sodium Hypochlorite (NaClO), Hydrogen Peroxide (H₂O₂).
    • Advanced Downstream: Polyvinyl Chloride (PVC), Surfactants, Chlorinated Paraffins, Coagulants, Epoxy Resins, and Formulated Household/Industrial Chemicals.
  • Established Industrial Foundation: Builds upon an operational domestic footprint (producing ~30k t/a caustic soda, ~26k t/a chlorine, ~45k t/a HCl, and ~6.6k t/a NaClO), mitigating brownfield integration and technology adoption risks.
  • Cross-Border Logistical Connectivity: Centrally located along major Eurasian transit corridors, utilizing 11 international transport corridors (6 road, 5 rail) and the Trans-Caspian International Transport Route (Middle Corridor) for cost-effective export into Central Asia, the Caucasus, Türkiye, and Europe.

Target Investor Profile & Next Steps

This investment opportunity is structured for:
  • Strategic global chemical producers seeking a cost-advantaged Eurasian production hub
  • Diversified industrial conglomerates and infrastructure investment funds
  • Private equity sponsors focused on basic materials, industrial real assets, and import-substitution platforms
Line Item Amount (US$ M) % of Revenue Strategic Notes
Gross Revenue $620.0 100.0% Blended sales: bulk chlor-alkali + premium downstream (PVC, resins, surfactants)
Raw Materials & Feedstock ($148.8) 24.0% Domestic salt advantage, ethylene/petrochem inputs, catalysts
Power & Utilities ($161.2) 26.0% Chlor-alkali electrolysis power intensity
Direct Labor & Plant O&M ($49.6) 8.0% Specialized chemical operators, regular turnaround maintenance
Logistics & Distribution ($37.2) 6.0% Rail/road freight across Central Asia & Middle Corridor
Cost of Goods Sold (COGS) ($396.8) 64.0% Total direct manufacturing costs
Gross Profit $223.2 36.0%
SG&A and Corporate Overheads ($37.2) 6.0% Commercial team, compliance, licensing, regional distribution offices
EBITDA $186.0 30.0% ~5.7x CapEx/EBITDA multiple (aligns with 5.7-yr simple payback)
Depreciation & Amortization (D&A) ($53.0) 8.5% Straight-line asset depreciation (~20-year operational life)
EBIT (Operating Income) $133.0 21.5%
Net Financing Costs ($38.0) 6.1% Indicative 60:40 debt-to-equity leverage structure
Earnings Before Taxes (EBT) $95.0 15.3%
Corporate Income Tax ($19.0) 3.1% Statutory 20% CIT rate (excl. potential SEZ tax incentives)
Net Income $76.0 12.3%

 

1. Informational & Preliminary Nature Only

This document, its appendices, and any accompanying materials (collectively, the “Materials”) have been prepared solely for preliminary informational and discussion purposes. Nothing contained herein constitutes, or shall be construed as:
  • An offer to sell, or a solicitation of an offer to purchase, any equity, debt, security, asset, or business enterprise.
  • Financial, investment, tax, legal, regulatory, or technical engineering advice.
  • A binding commitment, agreement, or obligation of any kind on the part of the project sponsors, preparers, advisors, or their respective affiliates (collectively, the “Disclosing Parties”).

2. Forward-Looking Statements & Financial Estimates

The Materials contain forward-looking statements, including—without limitation—financial forecasts, projected run-rates, Internal Rate of Return (IRR), Net Present Value (NPV), payback periods, Revenue, EBITDA, margins, capital expenditures (CapEx), market growth projections, and operational benchmarks.
These statements are inherently speculative, based on subjective assumptions, preliminary economic modeling, and current market conditions that are subject to substantial commercial, macroeconomic, geopolitical, and regulatory risks. No representation, warranty, or undertaking—express or implied—is made by the Disclosing Parties that any projection, forecast, target, or estimate will be achieved, realized, or proven accurate. Actual operational, financial, and market results may vary materially from those presented.

3. No Verification, Accuracy, or Completeness

The quantitative and qualitative information set forth herein has been compiled from internal estimates and external third-party sources believed to be reliable, but it has not been independently verified, audited, or authenticated. The Disclosing Parties expressly disclaim any and all liability or responsibility for the accuracy, completeness, reasonableness, or currency of the information, calculations, and statements contained within the Materials. The Disclosing Parties undertake no obligation to update, amend, rectify, or supplement these Materials after distribution.

4. Mandatory Independent Due Diligence

Any recipient of these Materials (“Recipient”) is solely responsible for conducting its own thorough, independent evaluation and due diligence. Recipients are strongly advised to retain their own independent legal, technical, financial, environmental, and tax advisors before evaluating, negotiating, or executing any transaction. Reliance on this document for any investment, financing, or corporate decision is strictly unauthorized and undertaken at the Recipient’s sole risk.

5. Exclusion & Limitation of Liability

To the maximum extent permitted by applicable law, neither the Disclosing Parties nor any of their respective directors, officers, employees, partners, agents, advisors, or representatives shall be liable for any loss, liability, damage, expense, or claim—whether direct, indirect, special, incidental, punitive, or consequential (including, without limitation, loss of business, lost profits, loss of opportunity, or wasted expenditure)—arising out of or in connection with the access, use of, or reliance upon these Materials or any omissions herein, regardless of the legal theory (contract, tort, negligence, strict liability, or otherwise).

6. Confidentiality & Restrictions on Distribution

These Materials are strictly confidential and proprietary. They are intended solely for the use of the intended individual or entity to whom they have been directly delivered. Acceptance of these Materials constitutes agreement that the Recipient will not copy, reproduce, extract, modify, disclose, or distribute this document, in whole or in part, to any third party without the prior written consent of the Disclosing Parties.
Detailed operational, technical, and commercial data rooms, as well as formal bilateral discussions, remain strictly contingent upon the execution of a definitive Non-Disclosure Agreement (NDA) and satisfactory investor qualification.

MergersCorp M&A
International As Seen On

  • brand 1
  • brand 1
  • brand 1
  • brand 1
  • brand 1